Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Call For National Pharmacare Program In Canada Grows Louder

Executive Summary

An advisory council established by the Canadian federal government is recommending the country implement a universal, single payer public pharmacare program.

You may also be interested in...



Canadian Drug Pricing Reforms Could Lead To Medicine Shortages

Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.

Canada: National Pharmacare Or ‘Fill The Gaps’?

A national pharmacare program in Canada could make it harder to access higher cost drugs.

Canada Plans New Agency To Negotiate Drug Prices & Tackle Soaring Costs

A proposed new drugs agency with the power to evaluate the effectiveness of medicines and negotiate prices with manufacturers is seen as the first step towards a national pharmacare program offering universal drug coverage in Canada.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS125519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel